LEPROT: A Drug Target / Disease Biomarker (G54741)

Target Name: LEPROT

NCBI ID: G54741

LEPROT

LEPROT: A Drug Target / Disease Biomarker

LEPROT is a drug target and a potential biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LEPROT is a transmembrane protein that is expressed in various tissues and cells in the body. It is composed of four distinct regions: an extracellular region (ER), a transmembrane region (TM), an intracellular region (IC), and an N-terminal region (NT).

The LEPROT protein is involved in various physiological processes in the body, including cell signaling, neurotransmission, and inflammation. It is a key regulator of the T-cell receptor (TCR), which is a critical molecule involved in the immune response. The TCR is composed of a variable region (V) and a constant region (C). The V region of the TCR contains the T-cell receptor alpha chain, which is responsible for recognizing specific antigens in the body. The C region of the TCR contains several interaction modules, including the Leucine-rich repeat (LRR), which is known for its role in protein-protein interactions.

LEPROT is a protein that is expressed in various tissues and cells in the body, including the brain, spinal cord, muscle, heart, and testes. It is also expressed in various types of cancer, including breast, ovarian, and prostate cancer.LEPROT has been shown to play a role in the development and progression of cancer. For example, studies have shown that LEPROT is overexpressed in various types of cancer, and that overexpression of LEPROT is associated with cancer-related symptoms.

In addition to its role in cancer, LEPROT is also involved in the development and progression of neurodegenerative diseases. For example, studies have shown that LEPROT is overexpressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Overexpression of LEPROT has been shown to contribute to the development and progression of these diseases.

LEPROT is also involved in the immune response. It is a key regulator of the T-cell receptor, which is responsible for recognizing and responding to antigens in the body. The T-cell receptor is composed of a variable region (V) and a constant region (C). The V region of the TCR contains the T-cell receptor alpha chain, which is responsible for recognizing specific antigens in the body. The C region of the TCR contains several interaction modules, including the Leucine-rich repeat (LRR), which is known for its role in protein-protein interactions.

LRR is a small protein that is composed of 21 amino acid residues. It is located at the C-terminus of the T-cell receptor and is involved in the regulation of the T-cell receptor. LRR has been shown to play a role in the development and progression of cancer, as well as neurodegenerative diseases.

In conclusion, LEPROT is a drug target and a potential biomarker for the treatment of various diseases, including cancer and neurodegenerative diseases. Its role in these diseases is characterized by its involvement in the regulation of the T-cell receptor and its expression in various tissues and cells in the body. Further research is needed to fully understand the role of LEPROT in these diseases and to develop effective treatments.

Protein Name: Leptin Receptor Overlapping Transcript

Functions: Negatively regulates leptin receptor (LEPR) cell surface expression, and thus decreases response to leptin. Negatively regulates growth hormone (GH) receptor cell surface expression in liver. May play a role in liver resistance to GH during periods of reduced nutrient availability

The "LEPROT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LEPROT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets